Ces Urol 2000, 4(2):20-26 | DOI: 10.48095/cccu2000009

The prognostic significance of imunohistochemical evaluation of p53 in tissue of superficial urinary bladder tumors

M. Babjuk1, J. Dušková2, J. Dvořáček1, C. Povýšil2, Z. Ibrahim1, L. Jarolím1, J. Novák1
1 Urologická klinika Všeobecné fakultní nemocnice a 1. lékařské fakulty Univerzity Karlovy v Praze a Katedra urologie IPVZ v Praze
2 II. patologicko-anatomický ústav 1. lékařské fakulty a Všeobecné fakultní nemocnice a Katedra patologie IPVZ v Praze

The assessment of prognostic factors plays important role in treatment preference chosen for patients with superficial urinary bladder tumors. The role of gene and protein p53 is often discussed in those circumstances. In stored specimens from 55 patients with superficial tumors of the urinary bladder we have investigated the p53 (antibody BP53-12-1) by imunohistochemic technique and we have evaluated the prognostic value of such statement. Newly we used a new method of finding's interpretation, based on a semiquantitative assessment by HSCORE using the computer technologies combined with the intensity of every individual cellular nuclei positivity. As the cut off line for p53 positivity determination we recommend the HSCORE value 200. Using this cutoff we have found disease recurrence in 67,9 % of p53 positive patients and in 19 % of p53 negative (p<0.01), disease progression in 42,9 % of patients with positive and in 9,5 % with negative findings (p<0.05).

Keywords: Superficial urinary bladder tumors, Prognostic factors, Imunohistochemic assessment of p53, HSCORE

Published: March 1, 2000 

Open full article

References

  1. Lutzeyer, W., Rübben, H., Dahm, H.: Prognostic parameters in superficial bladder cancer: An analysis of 315 cases. J Urol, 127, 1982, 2, 250-252. Go to original source... Go to PubMed...
  2. Lamm, D.L.: Long-term results of intravesical therapy for superficial bladder cancer. Urol Clin North Am, 19, 1992, 3, 573-580. Go to original source...
  3. Kurth, K.H., Denis, L., Bouffioux, C., Sylvester, R., Debruyne, F.M.J. et al.: Factors affecting recurrence and progression in superficial bladder tumours. Eur J Cancer 31A, 1995, 11, 1840-1846. Go to original source... Go to PubMed...
  4. Zlotta, A.R., Noel, J.-Ch., Fayt, I., Drowart, A., Van Vooren, J.-P. et al.: Correlation and prognostic significance of p53, p21WAF1/CIP1 and Ki-67 expression in patients with superficial bladder tumors treated with bacillus Calmette-Guerin intravesical therapy. J Urol, 161, 1999, 3, 792-798. Go to original source... Go to PubMed...
  5. Keegan, P.E., Lunec, J., Neal, D.E.: p53 and p53-regulated genes in bladder cancer. Brit J Urol, 82, 1998, 710-720. Go to original source... Go to PubMed...
  6. Pacík, D., Vít, V., Turjanica, M.: Intravezikální imunoterapie povrchového karcinomu močového měchýře BCG vakcínou. Rozhl Chir, 76, 1997, 10, 482-485.
  7. Babjuk, M.: Intravezikální instilace BCG vakcíny v léčbě povrchových nádorů močového měchýře. Prakt Lék, 77, 1997, 5, 238-240.
  8. Bártek, J., Iggo, R., Gannon, J., Lane, D.P.: Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines. Oncogene, 5, 1990, 893-899.
  9. Bacus, S., Flowers, J.L., Press, M.F., Bacus, J.W., McCarty, K.S., Jr.: The evaluation of estrogen receptor in primary breast carcinoma by computer-assisted image analysis. Am J Clin Pathol, 90, 1988, 233-239. Go to original source... Go to PubMed...
  10. Hollstein, M., Sidransky, D., Vogelstein, B., Harris, C.C.: p53 mutations in human cancers. Science, 253, 1991, 49-53. Go to original source... Go to PubMed...
  11. Spruck III, C.H., Ohneseit, P., Gonzalez-Zulueta, M., Esrig, D., Miyao, N. et al.: Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res, 54, 1994, 784-788.
  12. Reich, N.C., Oren, M., Levine, A.J.: Two distinct mechanisms regulate the levels of a cellular tumor antigen, p53. Mol Cel Biol, 3, 1983, 12, 2143-2150. Go to original source... Go to PubMed...
  13. Finlay, C.A., Hinds, P.W., Tan, T.-H., Eliyahu, D., Oren, M., Levine, A.J.: Activating mutations for transformation by p53 produce a gene product that forms an hsc70p53 complex with an altered half-life. Mol Cell Biol, 8, 1988, 2, 531-539. Go to original source... Go to PubMed...
  14. Cordon-Cardo, C., Dalbagni, G., Saez, G.T., Oliva, M.R., Zhang, Z.-F. et al.: p53 mutations in human bladder cancer: genotypic versus phenotypic patterns. Int J Cancer, 56, 1994, 3, 347-353. Go to original source... Go to PubMed...
  15. Sarkis, A.S., Dalbagni, G., Cordon-Cardo, C., Zhang, Z.-F., Sheinfeld, J. et al.: Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. J Natl Cancer Inst, 85, 1993, 1, 53-59. Go to original source... Go to PubMed...
  16. Sarkis, A.S., Zhang, Z.-F., Cordon-Cardo, C., Melamed, J., Dalbagni, G. et al.: p53 nuclear overexpression and disease progression in Ta bladder carcinoma. Int J Oncol, 3, 1993, 2, 355-360. Go to original source... Go to PubMed...
  17. Sarkis, A.S., Dalbagni, G., Cordon-Cardo, C., Melamed, J., Zhang, Z.-F. et al.: Association of p53 nuclear overexpression and tumor progression in carcinoma in situ of the bladder. J Urol, 152, 1994, 2, 388-392. Go to original source... Go to PubMed...
  18. Serth, J., Kuczyk, M.A., Bokmeyer, C., Hervatin, C., Nafe, R. et al.: p53 immunohistochemistry as an independent prognostic factor for superficial transitional cell carcinoma of the bladder. Br J Cancer, 71, 1995, 1, 201-205. Go to original source... Go to PubMed...
  19. Lipponen, P.K.: Over-expression of p53 nuclear oncoprotein in transitional-cell bladder cancer and its prognostic value. Int J Cancer, 53, 1993, 365-370. Go to original source... Go to PubMed...
  20. Underwood, M.A., Reeves, J., Smith, G., Gardiner, D.S., Scott, R. et al.: Overexpression of p53 protein and its significance for recurrent progressive bladder tumors. Br J Urol, 77, 1996, 5, 659-666. Go to original source... Go to PubMed...
  21. Vorreuther, R., Hake, R., Heidenreich, A., Thiele, J., Engelmann, U.: Der Wert immunohistochemischer Marker (PCNA, K-67, 486p und p53) in der Abschaetzung des Rezidivrisikos oberflaechlicher Blasenkarzinome. Akt Urol, 28, 1997, 2, 109-114. Go to original source...
  22. Esrig, D., Spruck, Ch.H. III, Nichols, P.W., Chaiwun, B., Steven, K. et al.: p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. Am J Pathol, 143, 1993, 5, 1389-1397.
  23. Raitanen, M.P., Tammela, T.L.J., Kallioinen, M., Isola, J.: P53 accumulation, deoxyribonucleic acid ploidy, and progression of bladder cancer. J Urol, 157, 1997, 4, 1250-1253. Go to original source... Go to PubMed...

Return to the content



Web časopisu Česká urologie je určen pouze pro lékaře a odborníky
z oblasti medicíny nebo farmacie.



Beru na vědomí, že informace zveřejněné na těchto stránkách
nejsou určeny pro laickou veřejnost.


Odejít Vstoupit